FORMULATION AND INVITRO EVALUATION OF GLIBENCLAMIDE SUSTAINED RELEASE TABLETS

This research endeavor aims to design and develop a robust and efficacious formulation of an oral antihyperglycemic drug, encapsulated in a sustained-release matrix tablet. The oral route of administration is widely regarded as the most natural, convenient, and safe, owing to its ease of administration, enhanced patient compliance, and cost-effective manufacturing process. Sustained-release dosage forms are meticulously designed to release the medication at a predetermined rate, thereby achieving and maintaining optimal therapeutic blood levels. The incorporation of sustained-release technology offers a multitude of benefits, including sustained blood levels, attenuation of adverse effects, and improved patient compliance. This study will undertake a comprehensive investigation of the effects of various formulation variables, such as polymer type and concentration, filler type, and tablet compression force, on the release characteristics of the drug. The optimized formulation will subsequently be evaluated for its stability, scalability, and in vitro release properties.